- Evolent Health recently reported their Q4/2021 earnings that revealed a solid beat on EPS and revenue. In addition, the company updated investors on their bullish outlook for 2022.
- The company is working on their 3 primary objectives of strong organic growth, expanding margins, and optimal capital deployment. It looks as if Evolent has the recipe and the ingredients.
- What is more, it appears as if EVH is trading at a reasonable valuation at this point in time.
- Considering its track record and potential for additional growth, I think EVH is a prime candidate for the Bioreactor Portfolio.
- I reveal my plan for initiating a position in EVH.
For further details see:
Evolent Health: Finding Steady Growth At An Acceptable Valuation